ArticleKidney research and clinical practice2026
Facility-level comorbidity burden and cardiovascular outcome in patients undergoing hemodialysis.
Article in Kidney research and clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThe impact of facility-level comorbidity burden on the prognosis of hemodialysis patients remains unclear. This study aimed to investigate the association between facility-level comorbidity burden and hemodialysis outcomes.
methodsWe examined 15,481 participants receiving hemodialysis at primary clinics participating in the Periodic Hemodialysis Quality Assessment by Health Insurance Review and Assessment Service in Korea. Facility-level comorbidity burden, defined as the sum of the Charlson Comorbidity Index of all patients divided by the number of nurses in each hemodialysis center, was the primary predictor. The primary outcome was major adverse cardiac and cerebrovascular events (MACCE).
resultsDuring a median follow-up of 6.8 years, MACCE and all-cause mortality occurred in 9,797 (63.3%) and 8,513 participants (55.0%), respectively. Participants in the highest facility-level comorbidity burden had the highest incidence rates of both MACCE and all-cause mortality. Hazard ratios (HRs) of MACCE and all-cause mortality in the highest vs. the lowest quartile were 1.10 (95% confidence interval [CI], 1.03-1.18) and 1.14 (95% CI, 1.06-1.22), respectively. Applying the facility-level comorbidity burden as a continuous variable, each 10-unit increase in facility-level comorbidity burden was associated with a 4% and 8% higher risk of MACCE and all-cause mortality, respectively. These associations remained consistent across subgroups.
conclusionOur findings revealed that the facility-level comorbidity burden in hemodialysis centers was associated with a higher hazard of poor outcomes in patients undergoing hemodialysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.